Browse everything: Tickers A–Z · Issuers · Comparisons · Tags
PRQR Stock — ProQR Therapeutics BV
ProQR Therapeutics BV (PRQR)
Updated October 16, 2026.
PRQR is a Stock. Total return is -91.1% over the past 12.1 years, 454.8 points behind SPY at 363.7%.
ProQR Therapeutics N.V. is a clinical-stage biotechnology company developing RNA editing medicines for genetic disorders, including lead candidate AX-0810 for cholestatic diseases and programs targeting Rett syndrome, metabolic dysfunction-associated steatohepatitis, and cardiovascular conditions through its Axiomer RNA editing platform. The company does not currently have an established distribution schedule. This security appeals to investors seeking exposure to early-stage biotechnology development with a focus on rare genetic disorders.
PRQR performance versus SPY
Price and return data through 2026-10-16.
Total return is -91.1% over the past 12.1 years, 454.8 points behind SPY at 363.7%. Over the past year its total return — price change plus distributions reinvested — is -53.2%. Its deepest 1-year drawdown was 57.0%.
| Window | Total return | CAGR |
|---|---|---|
| 1M | -29.6% | — |
| 3M | -21.6% | — |
| 6M | -32.8% | — |
| YTD | -35.1% | — |
| 1Y | -53.2% | — |
| 2Y CAGR | — | -42.90% |
| 3Y CAGR | — | 0.30% |
| 5Y CAGR | — | -30.10% |
| 10Y CAGR | — | -14.60% |
| Since inception (12.1 years) | -91.1% | -18.20% |
PRQR key facts
- Asset type
- Stock
- Asset class
- Equity
- Inception date
- 09/18/2014
- Distribution frequency
- None
- Last close
- $1.31 (as of 2026-10-16)
- Market cap
- $184,865,932
- Average volume
- 1064179.0
- Beta
- 0.2
- Payout ratio
- 0.0%
- EPS
- $-0.45
How Dividend Vision calculates yield and returns
Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.
Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology
Sources and review
Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.
Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.
PRQR risks and drawbacks
Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 57.0%.
Who may consider PRQR — and who may not
It is a weaker fit for investors who need monthly cash flow (PRQR does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.
More on PRQR
Frequently asked questions
Does PRQR pay monthly?
No. PRQR does not currently distribute.
When does PRQR pay a dividend?
PRQR does not currently distribute.
How has PRQR performed?
Total return is -91.1% over the past 12.1 years, 454.8 points behind SPY at 363.7%. Over the past year its total return — price change plus distributions reinvested — is -53.2%. Its deepest 1-year drawdown was 57.0%.
Tickers
Holdings as-of date unavailable.
| Ticker | Name | Weight |
|---|
See how this investment would fit into your portfolio.